{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059812","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.692901+00:00","generated_at":"2026-06-08T15:25:00.485237+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corbus Q3 net loss $10.1M; pipeline progress with CRB-701, CRB-601, CRB-913","bullets":["Net loss of $10.1M ($2.27 per diluted share) vs $8.8M ($2.11) in Q3 2022.","Cash, equivalents, and investments of $28.7M as of Sept 30, 2023.","CRB-701 Phase 1 dose escalation ongoing; early clinical data expected Q1 2024 alongside U.S./EU trial start.","IND submission for CRB-601 on track for Q4 2023; pre-clinical data presented at SITC.","CRB-913 pre-clinical study published in Obesity; shows no lean muscle loss when combined with incretins."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059812","json":"https://secwatch.observer/filing/0000950170-23-059812.json","markdown":"https://secwatch.observer/filing/0000950170-23-059812.md","text":"https://secwatch.observer/filing/0000950170-23-059812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/0000950170-23-059812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/crbp-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:25:00.485237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23e30e6cc497a6dd47618f9fdda6d3cddbc279ee","claim":"Corbus Pharmaceuticals Holdings, Inc. reported financial results for the third quarter of 2023.","evidence_excerpt":"today provided a corporate update and reported financial results for the third quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023059812/0000950170-23-059812-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}